News Sentiment

ORIC sentiment intelligence

Oric Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.85 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.8% over one week, +31.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.8% Price reacting lower
Trend fit Trend inactive 31.2% over four weeks
Fair value 14.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 7
Market source 6
GlobeNewswire 5
simplywall.st 4
Investing.com 3
Stock Traders Daily 2
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 11
Analyst action 4
Macro sensitivity 1
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47